Why 70% Quit GLP-1s: The Real Dropout Data

What They Found

This analysis examined real-world discontinuation patterns for GLP-1 receptor agonists and tirzepatide, revealing significantly higher dropout rates than seen in controlled trials. The study tracked patients across multiple healthcare systems to identify the primary reasons people stop these medications and the metabolic consequences of discontinuation.

Why It Matters

The disconnect between clinical trial persistence and real-world adherence tells the complete story about GLP-1 therapeutics that most practitioners never see. While pivotal trials for semaglutide showed 80-90% completion rates, real-world data consistently shows 12-month continuation rates around 30-40%. This isn't just about cost or access—it's about tolerance to the core mechanism.

GLP-1 receptor agonists work by delaying gastric emptying and enhancing satiety through central appetite regulation. But this same mechanism drives the nausea, vomiting, and gastrointestinal distress that forces many users to quit. Tirzepatide, with dual GLP-1/GIP receptor activity, theoretically should improve tolerance through GIP's gastric motility effects, but real-world discontinuation data will show whether this mechanistic advantage translates to better persistence.

The metabolic consequences matter more than most realize. When patients discontinue GLP-1 therapy, they typically regain 60-80% of lost weight within 12 months. More concerning is the rapid return of insulin resistance markers and inflammatory parameters that had improved during treatment. This isn't just weight regain—it's metabolic rebound.

What I'd Watch For

This type of analysis is only as good as its patient selection and follow-up methodology. Real-world studies often miss patients who switch between healthcare systems or go to cash-pay clinics. The most valuable data will separate discontinuation due to side effects versus cost/access barriers versus achieving weight goals.

The key question this study needs to answer: What predicts successful long-term use? Patient phenotype, starting dose protocols, and concurrent medications all likely influence persistence, but most discontinuation studies don't dig into these variables.

Bottom Line

High discontinuation rates are the reality of GLP-1 therapy, not an aberration. If you're prescribing these compounds, plan for it. Start lower, titrate slower, and have metabolic maintenance strategies ready for when patients stop.